NCT05055388

Brief Summary

Sepsis is still the main cause of maternal death, accounting for 11% of maternal deaths. Early identification of high risk factors of sepsis and early intervention can improve the prognosis of pregnant women with sepsis. At present, there is no epidemiological investigation report on sepsis in ICU in China.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
160

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Dec 2020

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 3, 2020

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

September 14, 2021

Completed
10 days until next milestone

First Posted

Study publicly available on registry

September 24, 2021

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2021

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2022

Completed
Last Updated

September 24, 2021

Status Verified

September 1, 2021

Enrollment Period

1.1 years

First QC Date

September 14, 2021

Last Update Submit

September 14, 2021

Conditions

Outcome Measures

Primary Outcomes (3)

  • The incidence of Maternal sepsis in intensive care unit

    The incidence of Maternal sepsis in ICU represents as proportion based on the total number of of maternal ICU admissions and is expressed per 100 deliveries.

    January 2008 to December 2019

  • Sepsis related maternal mortality

    Sepsis related maternal mortality in hospitals represents as proportion based on the total number of maternal sepsis in intensive care units and is expressed per 100,000 deliveries.

    January 2008 to December 2019

  • The incidence of multidrug resistance

    The incidence of multidrug resistance represents as proportion based on the total number of of maternal sepsis in ICU and is expressed per 100 deliveries. Multidrug resistance was defined as acquired non-susceptibility to at leas one agent in three or more antimicrobial categories.

    January 2008 to December 2019

Secondary Outcomes (2)

  • The length of ICU stay

    January 2008 to December 2019

  • Hospital length

    January 2008 to December 2019

Study Arms (2)

Group with sepsis complicated with multidrug-resistant bacteria

Obstetrics diagnosed with sepsis were divided to group with sepsis complicated with multidrug-resistant bacteria if microbial culture results showed multidrug-resistance.

Other: Multidrug-resistant bacteria

Group with sepsis complicated with none multidrug-resistant bacteria

Obstetrics diagnosed with sepsis were divided to group with sepsis complicated with none multidrug-resistant bacteria if microbial culture results showed none-multidrug-resistance or no positive result of microbial culture.

Interventions

Multidrug resistance was defined as acquired non-susceptibility to at leas one agent in three or more antimicrobial categories.

Group with sepsis complicated with multidrug-resistant bacteria

Eligibility Criteria

Age18 Years - 70 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Obstetrics with sepsis in any trimester of pregnancy or within 42 days of delivery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking University Third Hospital

Beijing, Beijing Municipality, 100191, China

Location

MeSH Terms

Conditions

Pregnancy Complications, Infectious

Condition Hierarchy (Ancestors)

InfectionsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Deputy chief doctors

Study Record Dates

First Submitted

September 14, 2021

First Posted

September 24, 2021

Study Start

December 3, 2020

Primary Completion

December 31, 2021

Study Completion

May 31, 2022

Last Updated

September 24, 2021

Record last verified: 2021-09

Data Sharing

IPD Sharing
Will not share

Locations